Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 8/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PTGIR | P43119 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14042630 | 0.88 | CYP2D6 (0.46) | SLC6A2SLC6A4SLC6A3CYP2D6HTR7 | |
| SCHEMBL3431955 | 0.86 | WDR5 (0.43) | WDR5CYP2D6HTR7 | |
| SCHEMBL4106143 | 0.84 | WDR5 (0.41) | WDR5SLC6A2SLC6A4CYP2D6HTR7 | |
| SCHEMBL4788240 | 0.82 | ADRA2A (0.44) | SLC6A2SLC6A4SLC6A3CYP2D6HTR7 | |
| SCHEMBL14042571 | 0.82 | PTGIR (0.39) | WDR5SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL4114349 | 0.82 | WDR5 (0.48) | WDR5SLC6A2SLC6A4CYP2D6HTR7 | |
| SCHEMBL3414421 | 0.80 | TAAR1 (0.42) | SLC6A2SLC6A4SLC6A3CYP2D6HTR7 | |
| SCHEMBL14042623 | 0.79 | PTGIR (0.47) | WDR5PTGIR | |
| SCHEMBL3431450 | 0.79 | WDR5 (0.46) | WDR5CYP2D6HTR7PTGIR | |
| SCHEMBL4106896 | 0.78 | WDR5 (0.48) | WDR5SLC6A2SLC6A4CYP2D6HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102036664-B | Selective subtype alpha 2 adrenergic agents and methods of use thereof | ALLERGAN INC | 2012-11-28 | — | — | CN | disclosed |
| CN-102036664-A | Selective subtype alpha 2 adrenergic agents and methods of use thereof | ALLERGAN INC | 2011-04-27 | — | — | CN | disclosed |
| EP-2265269-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | Allergan, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009120648-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009120648-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090239918-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239918-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239918-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239918-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | WDR5 3275/4885SLC6A2 60/4885SLC6A4 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.